ArticleMedical molecular morphology2026
Scavenger receptor class B type I (SR-BI) as a potential therapeutic target in multiple myeloma.
Article in Medical molecular morphology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple myeloma (MM) is a malignant plasma cell neoplasm characterized by marked biological heterogeneity and complex metabolic reprogramming. Although dysregulated lipid metabolism has been implicated in MM, its morphological correlations and clinical significance remain unclear. The present study evaluated cytoplasmic vacuoles in peripheral blood smears and analyzed their associations with the prognosis and stage of MM. Additionally, lipid droplet formation and the expression of key cholesterol regulatory molecules among MM cell lines were examined via molecular and biochemical approaches. Intracytoplasmic vacuoles were more frequently observed at advanced Revised International Staging System stages of MM, although no significant difference in overall survival was observed. MM cell lines exhibited prominent lipid droplet accumulation and upregulated acyl-coenzyme A:cholesterol acyltransferase-1 (ACAT-1) and scavenger receptor class B type I (SR-BI) expression. The pharmacological inhibition of SR-BI suppressed MM cell proliferation and induced apoptotic cell death, whereas the inhibition of ACAT-1 had only a modest effect. Ultrastructural analysis revealed marked cytoplasmic vacuolization following SR-BI inhibition. These findings indicate that altered cholesterol metabolism is closely associated with cytoplasmic vacuolization in MM cells, suggesting that SR-BI plays a critical role in MM cell survival. Therefore, targeting the cholesterol trafficking pathways may represent a potential therapeutic strategy in MM.
Indexed as
Identifiers
42268310What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.